Glioma

Gliomas are primary tumors that originate in the brain parenchyma. The complexity of gliomas is underscored by their heterogeneity, which poses significant challenges in treatment and management. Alfa Cytology is dedicated to pioneering new therapeutic avenues in glioma treatment for our clients.

Introduction to Glioma

There are different types of gliomas, which differ in terms of cellular characteristics, location, and severity. Some gliomas do not show any symptoms, but when they do, they indicate that the brain or spinal cord is being compressed. These tumors grow inside the brain parenchyma and often mix with normal brain tissue, making them difficult to remove surgically and characterized by short survival, high recurrence rates, high disability rates, and high mortality rates.

Fig.1 Cellular composition of glioma immune microenvironment. (Qi Y., et al., 2024)

Gliomas include astrocytomas, brainstem gliomas, ventricular meningiomas, mixed gliomas, oligodendrogliomas, glioblastoma multiforme, and optic gliomas. Nearly half of all primary brain tumors are astrocytomas. Malignant gliomas are the most serious form of malignant astrocytoma.

Therapeutic Development for Glioma

The therapeutic landscape for glioma has evolved significantly, transitioning from conventional surgical and radiotherapeutic approaches to more sophisticated molecularly targeted therapies and immunotherapeutics.

We summarize here current treatments and relevant clinical trials for glioma.

Our Services

At Alfa Cytology, we offer a comprehensive range of services designed to facilitate glioma diagnostics and therapy development.

Therapeutics Development

• Small Molecule Drug
• Radionuclide Therapy
• Therapeutic Antibody
• Peptide Drug
• Cell Therapy
• Gene Therapy
• Oncolytic Virotherapy
• Vaccine

Modeling Services

• Cell Line Development
• Organoids and Organ Chip Models
• Blood Brain Barrier Models
• Xenograft Models
• Syngeneic Models
• Virus-induced Models
• Transgenic Models
• Metastatic Models

Preclinical Research

• In Vitro Efficacy Evaluation
• In Vivo Efficacy Evaluation
• In Vitro ADME
• In Vivo PK
• Safety Assessment

Contact Us

For more information about our services or to discuss potential collaborations, please reach out to us at Alfa Cytology. Our dedicated team of biological experts is ready to assist you in advancing your research and therapeutic development efforts in glioma.

References

1. Qi Y.; et al. (2024). Immune checkpoint targeted therapy in glioma: status and hopes[J]. Frontiers in immunology. 2020, 11: 578877.
2. Rodríguez-Camacho, A.; et al. (2022). Glioblastoma treatment: state-of-the-art and future perspectives[J]. International journal of molecular sciences. 23(13), 7207.